---
title: "603456.SH (603456.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/603456.SH/news.md"
symbol: "603456.SH"
name: "603456.SH"
parent: "https://longbridge.com/en/quote/603456.SH.md"
datetime: "2026-05-20T13:54:51.449Z"
locales:
  - [en](https://longbridge.com/en/quote/603456.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/603456.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/603456.SH/news.md)
---

# 603456.SH (603456.SH) — Related News

### [Red Star Macalline target price increased by 100%, Jiuzhou Pharma and others' ratings downgraded | Brokerage Rating Observation](https://longbridge.com/en/news/285862436.md)
*2026-05-11T01:04:10.000Z*
> According to data from Nanfang Caijing Research, from May 6 to 10, brokerages made 353 adjustments to the target prices 

### [Jiuzhou Pharma: In 2026, facing factors such as the expiration of patents for major customer projects and rising raw material prices, the gross profit margin will experience certain fluctuations](https://longbridge.com/en/news/284079908.md)
*2026-04-25T10:56:00.000Z*
> Jiuzhou Pharma stated in a conference call that it expects fluctuations in gross margin in 2026 due to the expiration of

### [Jiuzhou Pharma: The development plan for 2026 will accelerate the implementation of small nucleic acid production capacity](https://longbridge.com/en/news/284079369.md)
*2026-04-25T10:34:39.000Z*
> On April 24th, Jiuzhou Pharma stated in a conference call that small nucleic acids are a key business focus for the comp

### [Jiuzhou Pharma released its first-quarter performance, with a net profit attributable to the parent company of 172 million yuan, a year-on-year decrease of 31.22%](https://longbridge.com/en/news/283848714.md)
*2026-04-23T13:58:50.000Z*
> Jiuzhou Pharma released its Q1 2026 performance, with revenue of 1.201 billion yuan, a year-on-year decrease of 19.43%; 

### [Jiuzhou Pharma: Obtained European CEP Certificate for Chemical Raw Materials](https://longbridge.com/en/news/280430732.md)
*2026-03-25T07:35:59.000Z*
> Jiuzhou Pharma announced that the company recently received the European Pharmacopoeia suitability certification for the

### [Jiuzhou Pharma's subsidiary has obtained the drug registration certificate for Hydrobromide Vortioxetine Tablets](https://longbridge.com/en/news/279222061.md)
*2026-03-16T07:54:04.000Z*
> Jiuzhou Pharma's wholly-owned subsidiary Jiuzhou Biopharmaceutical (Taizhou) Co., Ltd. recently obtained the drug regist

### [Zhongtai Securities: Strategically optimistic about the raw material pharmaceutical sector](https://longbridge.com/en/news/274886024.md)
*2026-02-04T23:53:05.000Z*
> Zhongtai Securities research report indicates a strategic optimism for the raw material drug sector: innovative drug hot

### [Jiuzhou Pharma: Received the approval notice for the listing application of citric acid tamsulosin chemical raw materials](https://longbridge.com/en/news/272802946.md)
*2026-01-16T08:05:37.000Z*
> Jiuzhou Pharma announced that it recently received the "Approval Notice for the Market Application of Chemical Raw Mater

### [Jiuzhou Pharma's subsidiary plans to participate in the investment of Jiaxing Longfeng Venture Capital Partnership (Limited Partnership)](https://longbridge.com/en/news/270464251.md)
*2025-12-22T08:40:06.000Z*
> Jiuzhou Pharma's wholly-owned subsidiary Hongzhou Investment plans to invest 10 million yuan in Jiaxing Longfeng Venture